Record Information |
---|
Version | 2.0 |
---|
Created at | 2006-05-22 15:12:27 UTC |
---|
Updated at | 2024-09-17 15:43:41 UTC |
---|
NP-MRD ID | NP0000985 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Canrenone |
---|
Description | Canrenone is the major metabolite of spironolactone. Spironolactone is a competitive aldosterone receptor antagonist (ARA), has traditionally been the treatment of first choice in idiopathic hyperaldosteronism (IHA) and for preoperative management of aldosterone producing adenoma (APA), and its therapeutic properties are attributable to active metabolite canrenone. Canrenone and the K+ salt of canrenoate are also in clinical use: They avoid the formation of intermediate products with anti-androgenic and progestational actions, resulting in a decreased incidence of side effects. (PMID: 10790593 ). |
---|
Structure | [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1 |
---|
Synonyms | Value | Source |
---|
SC-9376Canrenone | HMDB | 17-Hydroxy-3-oxo-17a-pregna-4,6-diene-21-carboxylic acid g-lactone | HMDB | 17-Hydroxy-3-oxo-17a-pregna-4,6-diene-21-carboxylic acid lactone | HMDB | 17a-(2-Carboxyethyl)-17b-hydroxyandrosta-4,6-dien-3-one lactone | HMDB | 17b-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid | HMDB | 20-Spiroxa-4,6-diene-3,21-dione | HMDB | 3'-(3-oxo-17b-Hydroxyandrosta-4,6-dien-17a-yl)-propionic acid lactone | HMDB | 3-(17b-Hydroxy-3-oxoandrosta-4,6-dien-17a-yl)propionic acid g-lactone | HMDB | 3-(17b-Hydroxy-3-oxoandrosta-4,6-dien-17a-yl)propionic acid lactone | HMDB | 3-(3-oxo-17b-Hydroxy-4,6-androstadien-17a-yl)propionic acid g-lactone | HMDB | Aldadiene | HMDB | Phanurane | HMDB | R.P., 11614 | HMDB |
|
---|
Chemical Formula | C22H28O3 |
---|
Average Mass | 340.4559 Da |
---|
Monoisotopic Mass | 340.20384 Da |
---|
IUPAC Name | (1'S,2R,2'R,10'R,11'S,15'S)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecane]-6',8'-diene-5,5'-dione |
---|
Traditional Name | (1'S,2R,2'R,10'R,11'S,15'S)-2',15'-dimethylspiro[oxolane-2,14'-tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecane]-6',8'-diene-5,5'-dione |
---|
CAS Registry Number | 976-71-6 |
---|
SMILES | [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1 |
---|
InChI Key | UJVLDDZCTMKXJK-WNHSNXHDSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as steroid lactones. These are sterol lipids containing a lactone moiety linked to the steroid skeleton. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Steroid lactones |
---|
Direct Parent | Steroid lactones |
---|
Alternative Parents | |
---|
Substituents | - Steroid lactone
- 3-oxosteroid
- Oxosteroid
- Cyclohexenone
- Gamma butyrolactone
- Tetrahydrofuran
- Cyclic ketone
- Lactone
- Ketone
- Carboxylic acid ester
- Organoheterocyclic compound
- Monocarboxylic acid or derivatives
- Carboxylic acid derivative
- Oxacycle
- Hydrocarbon derivative
- Organic oxide
- Organooxygen compound
- Organic oxygen compound
- Carbonyl group
- Aliphatic heteropolycyclic compound
|
---|
Molecular Framework | Aliphatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | 150 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | 2.68 | Hansch CH, Leo A and Hoekman DH. "Exploring QSAR: Hydrophobic, Electronic, and Steric Constraints. Volume 1" ACS Publications (1995). |
|
---|
Predicted Properties | |
---|
General References | - Mantero F, Lucarelli G: Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris). 2000 Feb;61(1):52-60. [PubMed:10790593 ]
- Tatipalli M, Siripuram VK, Long T, Shuster D, Bernstein G, Martineau P, Cook KA, Cristofoletti R, Schmidt S, Vozmediano V: Model-Informed Optimization of a Pediatric Clinical Pharmacokinetic Trial of a New Spironolactone Liquid Formulation. Pharmaceutics. 2021 Jun 8;13(6). pii: pharmaceutics13060849. doi: 10.3390/pharmaceutics13060849. [PubMed:34201093 ]
- Dahmana N, Mugnier T, Gabriel D, Favez T, Kowalczuk L, Behar-Cohen F, Gurny R, Kalia YN: Polymeric micelle mediated follicular delivery of spironolactone: Targeting the mineralocorticoid receptor to prevent glucocorticoid-induced activation and delayed cutaneous wound healing. Int J Pharm. 2021 Jul 15;604:120773. doi: 10.1016/j.ijpharm.2021.120773. Epub 2021 Jun 4. [PubMed:34090990 ]
- Young MJ, Kanki M, Karthigan N, Konstandopoulos P: The role of the mineralocorticoid receptor and mineralocorticoid-receptor-directed therapies in heart failure. Endocrinology. 2021 May 29. pii: 6288445. doi: 10.1210/endocr/bqab105. [PubMed:34050730 ]
- Cha J, Hong S, Lee J, Gwak J, Kim M, Kim T, Hur J, Giesy JP, Khim JS: Novel polar AhR-active chemicals detected in sediments of an industrial area using effect-directed analysis based on in vitro bioassays with full-scan high resolution mass spectrometric screening. Sci Total Environ. 2021 Jul 20;779:146566. doi: 10.1016/j.scitotenv.2021.146566. Epub 2021 Mar 17. [PubMed:34030261 ]
- Rong S, Tang X, Guan S, Zhang B, Li Q, Cai B, Huang J: Effects of Impeller Geometry on the 11alpha-Hydroxylation of Canrenone in Rushton Turbine-Stirred Tanks. J Microbiol Biotechnol. 2021 Jun 28;31(6):890-901. doi: 10.4014/jmb.2104.04002. [PubMed:34024892 ]
- Radloff J, Pagitz M, Andrukhova O, Oberbauer R, Burgener IA, Erben RG: Aldosterone Is Positively Associated With Circulating FGF23 Levels in Chronic Kidney Disease Across Four Species, and May Drive FGF23 Secretion Directly. Front Physiol. 2021 Apr 29;12:649921. doi: 10.3389/fphys.2021.649921. eCollection 2021. [PubMed:33995120 ]
- Pecori A, Buffolo F, Burrello J, Mengozzi G, Rumbolo F, Avataneo V, D'Avolio A, Rabbia F, Bertello C, Veglio F, Mulatero P, Monticone S: Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3655-e3664. doi: 10.1210/clinem/dgab290. [PubMed:33942084 ]
- Wagmann L, Vollmer AC, Lauder L, Mahfoud F, Meyer MR: Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis. Molecules. 2021 Mar 9;26(5). pii: molecules26051495. doi: 10.3390/molecules26051495. [PubMed:33803489 ]
|
---|